Chinese authorities did not renew a conditional approval of Green Valley Pharmaceuticals’ controversial Alzheimer’s disease ...

Anavex Life Sciences Corp (AVXL) reports a robust financial runway and unveils encouraging results for blarcamesine, despite ...

Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...

When Eli Lilly (LLY) posted strong quarterly results, the stock fell from $750 to $625.65 by August 8. Shareholders fretted about clinical results from its next-generation obesity drug. Its 37.7% Y/Y ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...